Visus Pharm

Visus Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic therapies to improve vision and ocular health. The company's lead product candidate, Brimochol PF, is a preservative-free, daily eye drop designed to treat presbyopia by optimizing pupil size through a combination of carbachol and brimonidine tartrate. Visus is also advancing a pipeline of candidates for other eye conditions, including glaucoma and age-related macular degeneration. With a focus on patient-centric solutions, the company aims to provide long-acting and well-tolerated treatments for millions of people worldwide. The firm is headquartered in Seattle with additional clinical operations in Southern California.